Register for OBR daily




To find out more about a company click on the company name to see a brief profile.

OBR Finance Top 5 Winners

CCXI $8.67 0.8700 +11.15%
VBLT $8.05 0.6700 +9.08%
FPRX $25.64 2.1200 +9.01%
ADXS $25.16 2.0400 +8.82%
AGEN $8.18 0.5600 +7.35%

Quotes Are Updated Every 20 Minutes. Companies with a Market Cap of less than $50M are not included.

OBR Finance Top 5 Losers

GALT $2.51 -0.2300 -8.39%
BMY $64.60 -4.5500 -6.58%
BPTH $1.20 -0.0800 -6.25%
XBIT $19.12 -0.8000 -4.02%
GALE $1.57 -0.0600 -3.68%

Quotes Are Updated Every 20 Minutes. Companies with a Market Cap of less than $50M are not included.

Archived News Headlines

We have been archiving all OBR daily news stories since March 2008. Use the box below to search our archives for specific articles and content.

Please note: we do not "host" news articles on our website. When a media source removes an article from their website the link becomes inactive, and you will only be able to see the date, title, first sentence and media source that published the article.

<< First | < Prev | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | Next > | Last >>

Component in Green Tea May Help Reduce Prostate Cancer in Men at High Risk, Moffitt Cancer Center Researchers Say

(Moffitt) May 27, 2015 - Prostate cancer is the second most common type of cancer in men and is predicted to result in an estimated 220,00 cases in the United States in 2015.
read press release 



Entolimod May be a Promising Treatment Option for Many Solid Tumors

(RPCI) May 27, 2015 - A collaborative team of researchers led by Alex A. Adjei, MD, PhD, FACP, of Roswell Park Cancer Institute (RPCI) will share results from the first clinical study of the anticancer effects of the novel agent entolimod at the American Society of Clinical Oncology’s (ASCO) 51st Annual Meeting in Chicago.
read press release 



Roswell Park Scientists Develop Mobile Application Software for Colon Cancer Survivors

(RPCI) May 28, 2015 — Features and results of the post-operative survival calculator to be presented at ASCO Annual Meeting 2015.
read press release 



Study Shows Colorectal Cancer Genetically Different in Older and Younger Patients

(UCCC/In the Lab blog) May 29, 2015 - CU study presented at ASCO 2015 offers early evidence of genetic differences between CRC in young and old patients, possibly pointing toward different treatments and strategies in combating the young form of the disease.
read article 



Genetic Analysis of Single Circulating Tumor Cells Shows High Intra-patient Heterogeneity

(Yahoo! Finance) May 29, 2015 - Epic Sciences announced today that the company will present single cell sequencing data, from metastatic castrate resistant prostate cancer patients, at the 2015 annual meeting of the American Society for Clinical Oncology.
read article 



Adaptive Biotechnologies and Collaborators to Present Eight Studies at the 2015 American Society of Clinical Oncology Annual Meeting Demonstrating the Relevance of Monitoring Immune Receptors as a New Class of Biomarkers

(TheStreet) May 29, 2015 - Adaptive Biotechnologies, the leader in next generation sequencing (NGS) to profile T- and B-cell receptors of the adaptive immune system, and its collaborators will present data demonstrating the utility of immunosequencing from tissue and blood in predicting and monitoring response in cancer at the 2015 ASCO® meeting in Chicago from May 29-June 2, 2015.
read article 



Biomarker Analysis Reveals Several Potential Treatment Targets in Subtype of Anal Cancer

(RPCI) May 29, 2015 - While squamous cell anal carcinomas are rare, representing only about 2% of digestive-system cancer diagnoses, these cancers, which are associated with the human papillomavirus (HPV), sometimes prove very difficult to treat, recurring or developing metastases following standard treatment.
read press release 



Merck Drug Helps Colon Cancer Patients With DNA Repair Defect

(Bloomberg) May 29, 2015 - A small study found that Merck & Co.’s immune system-triggering drug Keytruda shrank tumors in colon cancer patients with a specific gene flaw, showing that genetic tests may help identify those likely to benefit from immune therapy treatments.
read article 



Bristol's Opdivo Reduces Risk of Death From Common Lung Cancer

(Reuters) May 29, 2015 - Bristol-Myers Squibb Co's drug, Opdivo, improved survival for patients with the most common form of lung cancer, nearly doubling survival for those with high levels of a specific protein in their tumors compared with chemotherapy, according to clinical trial results presented on Friday.
read article 



New Class of Drugs Shows More Promise in Treating Cancer

(New York Times) May 29, 2015 - A new drug that unleashes the body’s immune system to attack tumors can prolong the lives of people with the most common form of lung cancer, doctors reported on Friday, the latest example of the significant results being achieved by this new class of medicines.
read article 



Merck Immunotherapy Appears Effective in Head and Neck Cancer: Study

(Reuters) May 29, 2014 - A Merck & Co drug that helps the immune system fight cancer was about twice as effective as the current standard therapy for patients with recurrent or advanced head and neck cancers, according to study data released on Friday.
read article 



ASCO '15: Merck, Bristol Drugs Boost Immune System to Kill Broad Swath of Cancer Types

(TheStreet) May 29, 2014 - Four clinical trials involving the checkpoint inhibitors from Merck and Bristol-Myers Squibb are showing promising signs of efficacy in a wide range of solid tumors, according to results unveiled for the first time Friday at the start of the American Society of Clinical Oncology (ASCO) annual meeting.
read article 



Researchers Developing New Targeted and Immune Therapies for Colorectal Cancer Molecular Subtypes

(Fox Chase) May 27, 2015 - Researchers from Fox Chase Cancer Center in Philadelphia recently collaborated with Caris Life Sciences®, a biotechnology company headquartered in Dallas-Fort Worth, Texas, to conduct three separate studies related to precision medicine, particularly in colorectal cancers.
read press release 



Transgenomic Launches EGFR CLIA Test That Accurately Detects Key Mutations in Solid and Liquid Patient Samples Using Multiplexed ICE COLD-PCR™

(Transgenomic) May 29, 2015 - Transgenomic, Inc. today announced the launch of its new Multiplexed ICE COLD-PCR™ (MX-ICP) CLIA service for mutation detection in cancer patients to enable more informed diagnoses, better treatment decisions and ongoing patient monitoring.
read corporate press release 



ASCO Conference Data Show bioTheranostics’ Molecular Tests Significantly Impact Management of Metastatic Cancer Patients

(Morningstar) May 28, 2015 - bioTheranostics, Inc., today announced that clinical study data disclosed at the American Society of Clinical Oncology (ASCO) annual meeting demonstrate that its CancerTYPE ID® molecular cancer classifier and CancerTREATMENT NGS+ biomarker tests provide actionable genomic information to support an accurate diagnosis and treatment of metastatic cancers.
read article 



Myriad Significantly Advances the myChoice(R) HRD(TM) Companion Diagnostic Test

(Myriad) May 29, 2015 - Myriad Genetics, Inc. today announced new clinical studies on its myChoice HRD companion diagnostic test at the 2015 American Society of Clinical Oncology annual meeting being held in Chicago, Ill.
read corporate press release 



Myriad Presents New myRisk(TM) Hereditary Cancer Data at 2015 ASCO Annual Meeting

(Myriad) May 29, 2015 - Myriad Genetics, Inc. today announced it will highlight several new clinical studies on its myRisk Hereditary Cancer molecular diagnostic test at the 2015 American Society of Clinical Oncology annual meeting being held in Chicago, Ill.
read corporate press release 



Melanoma Rates Dramatically Increasing in Children and Young Adults

(RPCI) May 28, 2015 - The incidence of melanoma, a deadly form of skin cancer, has increased by more than 250% among children, adolescents and young adults since 1973, according to award-winning research to be presented by Roswell Park Cancer Institute (RPCI) at the American Society of Clinical Oncology (ASCO) 51st Annual Meeting in Chicago.
read press release 



Positive Data With Delcath's CHEMOSAT Highlighted at ASCO 2015

(Yahoo! Finance) May 29, 2015 - Delcath Systems, Inc., a specialty pharmaceutical and medical device company focused on oncology with an emphasis on the treatment of primary and metastatic liver cancers, announces that results of a large, European single-center experience of the treatment of uveal melanoma patients with hepatic metastases with the Delcath Hepatic CHEMOSAT® Delivery System, were highlighted in an on-line abstract at ASCO 2015.
read article 



Novocure Announces First Analysis of Full 700 Patient Dataset from Successful Newly Diagnosed GBM Phase III Trial

(Novocure) May 28, 2015 - Novocure, a commercial stage oncology company, announced today that the first analysis of all 700 newly diagnosed glioblastoma (GBM) patients enrolled in its EF-14 Phase III trial confirms that Tumor Treating Fields (TTFields) delivered in combination with standard-of-care temozolomide chemotherapy extends both progression-free survival (PFS) and overall survival (OS) compared to temozolomide alone in patients with newly diagnosed GBM.
read corporate press release 



JAK2 Inhibitor Ruxolitinib Has Minimal Toxicity, Promising Efficacy in Chronic Myelomonocytic Leukemia Patients, Say Moffitt Cancer Center Researchers

(Moffitt) May 29, 2015 - Chronic myelomonocytic leukemia (CMML) is a rare type of myelodysplastic, myeloproliferative neoplasm characterized by increased numbers of peripheral monocytes and less than 20 percent blasts.
read press release 



Moffitt Cancer Center Researchers Report that MEDI4736 Combined with Tremelimumab Results in Acceptable Toxicity, Clinical Activity in Non-Small Cell Lung Cancer Patients

(Moffitt) May 29, 2015 - Advanced non-small cell lung cancer (NSCLC) patients have few effective treatment options and low 5-year survival rates.
read press release 



Nivolumab Treatment in Melanoma Patients has Manageable Safety Profile, Additional Immunomodulatory Agents Do Not Affect Response Rates, Say Moffitt Cancer Center Researchers

(Moffitt) May 28, 2015 - The monoclonal antibody nivolumab has shown promise as a therapeutic agent, particularly by improving the survival rates of melanoma patients.
read press release 



Heron's Nausea Drug Meets Goal in Late-Stage Trial, Shares Soar

(Reuters) May 28, 2015 - Heron Therapeutics Inc said its experimental drug for treating chemotherapy-induced nausea and vomiting (CINV) met its main goal in a late-stage trial.
read article 



New Immunotherapies for Multiple Hard-to-Treat Cancers

(ASCO) May 29, 2015 - Findings from four clinical trials released today at the American Society of Clinical Oncology’s (ASCO) 51st Annual Meeting show a promising new role for immunotherapy in patients with a wide range of common, solid tumor cancers.
read press release